NOXXON gets FDA orphan drug status for olaptesed pegol to treat glioblastoma
Olaptesed pegol is a PEGylated mirror-image (L-) oligonucleotide, which binds and neutralizes the chemokine CXCL12/SDF-1, preventing interaction with its receptors CXCR4 & CXCR7. The company develops a new
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.